Dr. Mark Hyman

And in these articles, they named the claimants and statin deniers, including you.

which isn't actually true, and they accused you and your colleagues of spreading misinformation about statins, which they described as, quote, deadly propaganda.

The newspaper's article suggested that their statements led people to avoid taking statins, which was a big public health risk.

In response to these articles, your colleagues filed a defamation lawsuit, arguing that these articles falsely portrayed them as deliberately spreading lies about statins.

Now, the High Court has seen multiple legal arguments, particularly around the public interest defense under the Defamation Act of 2013 in the UK.

But in 2024, just recently,

The case was ruled in favor of your colleagues, against the newspaper.

So in some ways, you've been vindicated by the legal system that what you're raising in terms of concerns about Stans, and I'm kind of quoting from you at this point, which is their data is flawed on Stans.

it's over-emphasized, it's over-prescribed, it has risks, and there are other factors that need to be considered that are often being missed.

And it's a more nuanced view that you have.

It's not just drugs are bad, food is good, or drugs are bad and wheatgrass is good.

It's basically looking at very nuanced science to help unpack what we know and what we don't know about cholesterol and cardiovascular risk.

So

Walk us through what happened with that case and what the findings were and how you have all been vindicated as a result of the legal decision around this court case that was basically defending you, essentially.

You weren't directly involved in the final suit, but you were kind of part of the whole thing, you said.

You have your corner in hell all picked out.

So listen, I want to double click on that for a second.

Just so people understand, um,

We think academic institutions are squeaky clean, they're neutral, they're objective, they're scientific, medical schools, researchers.

But the truth is that a lot of their funding comes from pharma who are funding trials that they're executing.